Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metabolism, Inborn Errors: later-stage trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Metabolism, Inborn Errors: 3 US clinical trials tracked, none currently recruiting.
Metabolism, Inborn Errors is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Kastle Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition metabolism-inborn-errors
OPEN 0 | RECR 0% | LATE 2 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Metabolism, Inborn Errors has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metabolism, Inborn Errors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metabolism, Inborn Errors is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Kastle Therapeutics
NCT00694109
North Carolina Newborn Exome Sequencing for Universal Screening
University of North Carolina, Chapel Hill
NCT02826694
Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia
National Heart, Lung, and Blood Institute (NHLBI)
NCT00099996
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Metabolism, Inborn Errors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metabolism, Inborn Errors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metabolism, Inborn Errors page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Metabolism, Inborn Errors trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Kastle Therapeutics sponsors the most Metabolism, Inborn Errors trials on record, review their full trial history before evaluating a specific study. See Kastle Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metabolism, Inborn Errors condition card totals 3 registered trials; most-linked intervention Diagnosed, whole exome sequencing; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.